ClinicalTrials.gg
CompletedNCT04958746Updated Jun 2, 2022

Phase III Clinical Trial Evaluating the Efficacy and Safety of Ciprofol Injection for the Induction of Sedation/Anesthesia in Subjects Undergoing Gynecological Outpatient Surgeries

A Phase 3 interventional study of Ciprofol and Propofol in Gynecological Outpatient Surgery, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-06-02.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

This study is a multi-center, randomized, double-blind, Propofol parallel-controlled phase III clinical study, with the primary objective of evaluating the efficacy of Ciprofol vs. Propofol for the induction of sedation/anesthesia in subjects undergoing gynecological outpatient surgeries and secondary objective of evaluating the safety of Ciprofol in subjects undergoing gynecological outpatient surgeries.

02

Conditions studied

  • Gynecological Outpatient Surgery
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient needing gynecological outpatient surgery under general anesthesia without endotracheal intubation;
  2. Female, aged between 18-65 (inclusive);
  3. (ASA) Class I- II
  4. (BMI) ≥ 18 and ≤ 30 kg/m2;
  5. Vital signs during the screening period meet the following criteria:

    1. Respiratory rate ≥ 10 and ≤ 24 breaths/min;
    2. Pulse oxygen saturation (SpO2) ≥ 95% when inhaling;
    3. Systolic blood pressure (SBP) ≥ 85 mmHg and ≤ 140 mmHg;
    4. Diastolic blood pressure (DBP) ≥ 50 mmHg and ≤ 90 mmHg;
    5. Heart rate ≥ 50 beats/min and ≤ 100 beats/min. (Note: For heart rate, the heart rate results of 12- examination are used as the basis for judging whether the inclusion criteria are met.)
  6. Capable of understanding the procedure and method of this study, willing to sign an form and to complete this study in strict accordance with the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Patients with to deep sedation/general anesthesia or a history of past sedation/anesthesia accidents;
  2. Known sensitivity to Propofol Injection, Ciprofol Injection, the in the drugs (soybean oil, glycerin, triglyceride, egg lecithin, purified lecithin, sodium oleate, sodium hydroxide and disodium edetate), and opioids or any ingredient of opioids; contraindications to Propofol;
  3. Patients with positive urine HCG or blood HCG (except abortion, dilatation and curettage, other outpatient surgeries for termination of pregnancy);
  4. Patients having the following medical history or evidence prior to screening, which may increase sedation/anesthesia risk:

    1. History of cardiovascular diseases: Uncontrolled hypertension or SBP > 140 mmHg and/or DBP > 90 mmHg despite antihypertensive treatment, severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within 6 months prior to screening, history of tachycardia/bradycardia requiring medication, third-degree atrioventricular block or interval ≥ 450 ms (Fridericia's correction formula) during screening;
    2. Respiratory system disorders: Respiratory insufficiency, history of obstructive pulmonary disease, history of bronchospasm requiring treatment within 3 months prior to screening, acute respiratory tract infection with any one of the obvious symptoms such as fever, wheezing, or productive cough within 1 week prior to screening;
    3. History of neurological and mental disorders: history of craniocerebral injury, convulsions, epilepsy, intracranial hypertension, cerebral aneurysm, or cerebrovascular accident; history of schizophrenia, mania, chronic use of antipsychotics, cognitive impairment, etc.;
    4. History of gastrointestinal diseases: history of gastrointestinal retention, active hemorrhage, gastroesophageal reflux or obstruction, etc. which may cause reflux and aspiration, as per the judgment of the investigator;
    5. History of uncontrolled and diseases in such as liver, kidney, blood system, nervous system, or metabolic system judged by the investigator to be unsuitable for this trial;
    6. History of alcohol abuse within 3 months prior to screening, abuse defined as average of > 2 units of alcohol per day (1 unit = 360 mL of beer or 45 mL of liquor with 40% alcohol or 150 mL of wine);
    7. History of drug abuse within 3 months prior to screening;
    8. Serious infection, trauma, or major surgery within 4 weeks prior to screening.
  5. Patients with the following airway management risks at screening:

    1. Asthma history, and stridor;
    2. Sleep apnea syndrome;
    3. History or family history of malignant hyperthermia;
    4. History of intubation failure;
    5. Judged by the investigator to have difficult airway or judged as difficult tracheal intubation (modified Mallampati score III or IV).
  6. Receiving any one of the following medications or treatments at screening:

    1. Participated in other clinical trials of drugs within 1 month prior to screening;
    2. Used Propofol, other general sedatives/anesthetics, and/or opioid analgesics or compounds containing opioid analgesics within 3 days prior to screening.
  7. Patient whose laboratory parameters measured at screening meet any of the following criteria and are verified through reexamination:

    1. \< 1.5 × 109/L;
    2. count \< 80 × 109/L;
    3. \< 90 g/L;
    4. (ALT) or aspartate aminotransferase (AST) > 3.0 × (ULN)
    5. Total > 2 × ULN;
    6. Serum creatinine > 1.5 × ULN.
  8. Breastfeeding females; women of who are unwilling to use during the trial; or subjects who are planning pregnancy within 1 month after completion of the trial.
  9. Subject judged by the investigator to have any other factors unsuitable for participation in the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Ciprofol

    Ciprofol group:0.4/0.2mg/kg

    Drug: Ciprofol

  • Placebo comparator
    Propofol

    Propofol group:2.0/1.0mg/kg

    Drug: Propofol

Interventions

  • intravenous bolus

  • DrugPropofol

    intravenous bolus

06

What researchers measure

Primary outcomes

  1. Success rate of anesthesia

    The proportion of subjects successfully anesthetized in all subjects of the group.

    Time frame: Day 1

Secondary outcomes

  1. Time to successful sedation/anesthetic induction

    Time from the initial administration of the investigational drug to the first time when MOAA/S is ≤ 1

    Time frame: Day 1

  2. Time to full recovery:

    Time from the last administration of the investigational drug to the first of 3 consecutive MOAA/S scores = 5

    Time frame: Day 1

  3. Time to discharge

    The time from the last administration of the investigational products to the first of 3 consecutive Aldrete scores of ≥ 9

    Time frame: Day 1

  4. Sedation/anesthesia satisfaction, including satisfaction evaluation of subjects, anesthesiologists, and surgeons.

    Time frame: Day 1

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Sep 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2021
First posted
Jul 12, 2021
StartActual
Jul 26, 2021
Primary completionActual
Sep 29, 2021
CompletionActual
Sep 30, 2021
Last update
Jun 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04958746
Responsible party
Sponsor
First posted
Jul 12, 2021
Start date
Jul 26, 2021
Primary completion
Sep 29, 2021
Completion
Sep 30, 2021
Last update
Jun 2, 2022

Study contacts

Dongxin Wang
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion